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Editor: Karin Dumstrei 1st Editorial Decision 20 July 2012
Thank you for submitting your manuscript (EMBOJ-2012-82683) to our editorial office. I have now had a chance to read it carefully and to discuss it with my colleagues, and I am sorry to say that we cannot offer publication in The EMBO Journal.
Your analysis reports on the regulation of fimbrial gene expression in Salmonella enterica. The findings support that the fim operon represses PefA expression via CsrB and CsrC, while CsrA is a positive regulator of PefA. The findings further show that the 5'UTR of the fimAICDHF transcript is sufficient to repress PefA expression and that it binds CsrA. A model is proposed whereby the fimAICDHF transcript sequesters CsrA to prevent it from activating the expression of the Pef operon. We appreciate that the analysis provides support for that an mRNA can regulate the activity of a global regulator such as CrsA. However there is also limited further data provided in support of how CsrA regulates the expression of the PefA, if other targets /processes of CsrA are also affected upon expression of fimAICDHF mRNA and the physiological significance of the described regulatory mechanism. We therefore find that the advance and insight provided is not sufficient to consider publication in the EMBO Journal.
Please note that we publish only a small percentage of the many manuscripts that we receive at the EMBO Journal, and that we can therefore subject to external review only those submissions that have a good chance of timely acceptance. I am sorry to disappoint you on this occasion, but I hope that this negative decision will not prevent you from considering the EMBO Journal for publication of future studies.
Resubmission 04 March 2013
Thank you for handling our previous submission EMBOJ-2012-82683 entitled "Hierarchical regulation of fimbriae in Salmonella enterica serotype Typhimurium via a novel CsrA titration mechanism". You acknowledged in your decision letter of 07-20-2012 that you appreciated we had elucidated an unprecedented mechanism by which a messenger RNA can control the function of a global regulatory protein to establish hierarchical control of fimbrial gene expression in S. Typhimurium. However, you pointed out that the advance and insight provided by our study was not sufficient for publication in EMBO Journal because 1) limited data was provided in support of how CsrA regulates the expression of PefA, 2) we did not address if other targets of CsrA are also affected upon expression of fimAICDHF mRNA and 3) the physiological significance of the described regulatory mechanism was not established.
We have worked diligently to address these three shortcomings of our previous submission. 1) We performed additional experiments to elucidate the mechanism by which CsrA activates expression of PefA and these data are now included in three new figure panels ( Fig. 3D-F) . 2) We performed additional experiments demonstrating that expression of fimAICDHF mRNA affects expression of other CsrA-regulated targets and these data are now included in two new figure panels ( Fig. 5B and 5C ). 3) Finally, we performed mouse experiments suggesting that the described regulatory mechanism limits the costly production of plasmid-encoded fimbriae to host environments. These data illustrating the physiological significance of our study are now included in two new figure panels (Fig. 6A and 6B) in the revised manuscript. Inclusion of these new data has helped us to significantly strengthen our study by addressing all shortcomings pointed out in your decision letter of 07-20-2012. We thus respectfully request that you reconsider subjecting our manuscript to external review.
2nd Editorial Decision 04 April 2013
Thank you for submitting your manuscript to the EMBO Journal. Your study has now been seen by two referees and their comments are provided below.
As you can see below both referees appreciate the analysis and find it insightful. However more work is needed. Referee #2 raises relative minor issues with the analysis while referee #1 brings up more significant ones. I will not list them all here, but the CsrA binding sites in the 5'UTRs of fim and pet transcripts need to more precisely mapped, and a better analysis is needed to determine the in vivo copy number of CsrB, C and A and how this impact the proposed regulatory cascade. Should you be able to significantly extend the work and address the raised concerns in full then we would consider a revised manuscript. I should add that it is EMBO Journal policy to allow only a single round of revision and that it is therefore important to address the raised concerns at this stage.
When preparing your letter of response to the referees' comments, please bear in mind that this will form part of the Review Process File, and will therefore be available online to the community. For more details on our Transparent Editorial Process, please visit our website: http://www.nature.com/emboj/about/process.html Thank you for the opportunity to consider your work for publication. I look forward to your revision.
REFEREE REPORTS
Referee #1
This manuscript by Sterzenbach et al. (Hierarchical regulation of fimbriae in Salmonella enterica serovar Typhimurium via a novel CsrA titration mechanism) aims to present a novel posttranscriptional mechanism whereby type I fimbrial genes may influence the expression of plasmid-encoded fimbriae, an observation reported earlier by the same group.
Here, the authors analyze the expression of the pefACDEF genes as a function of the presence of the fimAICDHF, sirA, and csrABC genes, all of which are either known or predicted to be involved in the CsrA-mediated regulatory circuitry. These experiments seem to suggest that the RNA-binding protein CsrA is a positive regulator of pefACDEF expression and that this activity of CsrA is competed for by fimAICDHF transcripts. The authors then present the binding of both fimbrial 5' UTRs to CsrA and claim that the effect observed in the experiments above is direct. Finally, seeking the biological significance of this phenomenon, they measure the levels of both fimbrial transcripts in vivo and demonstrate an upregulation of pefACDEF upon infection in mice.
Although the regulatory model proposed in this paper does not lack certain elegance and seems to be sound and straightforward, the current evidence provided in support of it is insufficient and sometimes contradictory.
Major citicism:
1. A critical parameter of the model is the abundance of the fimAICDHF transcript(s), especially of the 5' UTR of fimA which is the predicted effector in regulation of CsrA. Using qRT-PCR, the authors showed that the copy number of this 5' UTR is unusually high, compared not only to known mRNA targets of CsrA but also to the extremely abundant non-coding RNAs CsrB and CsrC. However, qRT-PCR is not appropriate a method to address such a question, especially taking into account that plasmid DNA was used as quantification standard. In addition, Fig. 5A does not provide a negative control (ΔfimAICDHF) showing that the amplification is actually specific and not a mere result of contribution by an unrelated sequence. If the transcript is truly so abundant there should be no problem to detect it by Northern blot (at least in a dot blot version) or primer extension versus a range of in vitro transcribed RNA standards. More linear and direct methods as those latter two should be used to determine the in vivo copy numbers of CsrB, CsrC and the 5' UTRs in question, both free and bound to CsrA.
2. The next problem arising from the present copy number estimates is the actual numbers and potencies of CsrA binding sites. Even though CsrB appears to be 3 to 4 times less abundant than the 5' UTR of fimAICDHF, it still has 18 binding sites for CsrA versus 2 on the fimbrial messenger. This gives an about threefold higher absolute number of CsrA binders provided by CsrB/C, compared to the 5' UTR of fimAICDHF. The Kd for the 5' fimAICDH-CsrA complex estimated by EMSA (Fig. 4D ) appears to be close to 150 nM, which is way above the 20 pM (!) Kd reported earlier for CsrB (Martinez et al., Mol Microbiol 2011) . Given these simple calculations, it is very hard to understand that csrBC or sirA deletions have less an effect on pefACDEF expression than the deletion of fimAICDH (Figures 1A, and 3C) . Considering those aforementioned parameters, the 5' UTR of fimAICDHF simply would not have enough clout to impose any kind of CsrA-mediated regulation on pefACDEF.
3. It would generally be helpful if the authors mapped the binding sites of CsrA in the 5' UTRs of the fim and pet transcripts more precisely, e.g. using RNA footprinting methods or a more extensive mutational analysis.
4. The conclusion that CsrA does not affect fimAICDH expression seems incorrect. Moreover, it directly contradicts the results reported in the cited paper by Teplitski et al. 2006 (in Microbiology) . Figure 1C of the present manuscript suggests that in a sirA background, fimA is less expressed at the protein level than in WT. Figure 4D -E shows that the 5' UTR of fimAICDHF interacts with CsrA in vitro. Thus, it is likely that CsrA directly represses fimAICDHF translation. These observations can be interpreted to suggest that it one of the protein products encoded by the fimAICDHF operon--rather than its 5' UTR--is responsible for the effect on pefACDEF. Obviously, this effect would also be CsrA-dependent but would be very different from the mechanism currently proposed by the authors.
5. The latter impression is further strengthened by the results of overexpression of the 5' UTR of fimAICDHF. First, let us consider the title of the section on p. 9 "The 5'-UTR of the fimAICDHF transcript is sufficient for suppressing PefA expression". The most straightforward experiment to support such a claim is to measure the PefA level in a strain where only the ORFs of the fimAICDHF operon are deleted while the 5' UTR is preserved and expressed under control of its native promoter. This has not been done. Instead, the authors decided to overexpress the 5' UTR which, by the way, may accumulate to transcript levels (RNA copy number) far above that of the native mRNA. Surprisingly, Fig. 5A shows that the "overexpression" yielded much less transcript from the 5' UTR of fimAICDHF than the native promoter. Unexplainably, these levels were fully sufficient to repress pefA expression in Fig. 4C but failed to produce any noticeable effect on flhDC/fliC, as stated on page 12. Then the authors used another construct where fimAC were included together with the 5' UTR. This construct still performed very poorly on the flhD and fliC control targets of CsrA (note that one cannot interpret the statistical significance as evidence of a biologically relevant difference which is tiny - Fig. 5B-C) . On the other hand, it produced a very convincing effect (~100-fold reduction) on pefA ( Fig. 5D ) suggesting that the latter would be the only regulated target by fimAICDHF through CsrA. This substantially weakens the authors' claim that CsrA mediates any effect of one fimbrial operon on the other.
6. The experiments with the mutated putative CsrA binding site in the 5' UTR of pefACDEF are not convincing. Figure 3F shows that the PefA level is drastically decreased in the mutated strains. Figure 6B suggests that this defect is caused by destabilization of the pefACDEF transcript. Although the authors propose that CsrA competes with RNase E and thus activates expression of the operon, at current this is a mere inference from a recent story from the Romeo and Babitzke labs on a different CsrA regulated mRNA (Yakhnin et al., Mol Microbiol 2013) . Importantly, the comparison which should normally be considered on Figure 6B is the one between the levels of pefACCA in the inoculum and in the cecum. It clearly shows that pefACCA is still upregulated with a fold-change similar to other strains. Thus, CsrA does not play an important part in this upregulation event. Instead, one would suggest that the mutation affects the pefACDEF mRNA stability via a different mechanism (e.g. disruption of a secondary structure close to the 5' end increases its accessibility, accelerates decapping and improves processivity of RNase E).
Minor points:
7. It is unclear whether the levels of fimAICDHF measured throughout the paper correspond solely to the 5' UTR or the ORFs follow the same pattern. Can it be that the 5' UTR is abundantly expressed as an independent noncoding transcript? A quick PUBMED search suggests that there are a couple of published RNA-seq data sets for Salmonella, so this can easily be checked.
8. The quality of the EMSA experiment in Figure 3 is poor. A better resolution and the use of positive and negative controls is necesseary.
9. The decision to use the ΔcsrBC background on Fig. 5B -C, as it is justified on p. 13, is puzzling. CsrA activates the flhDC mRNA whereas both CsrB/C and the fim 5' UTR are supposed to counteract this influence. Why do the authors think there would be a better chance to see an effect of fim 5' UTR overexpression on flhDC if they essentially weaken the extent of CsrA sequestration by removing the CsrB/C RNAs and thus contribute to the flhDC activation?
10. The manuscript would benefit from correcting the usage of statistical terms. First, the test by which the p values are calculated should be explicitly named. Second, if the authors stick to the notion of statistical significance they cannot afford sentences like "While introduction of pTS42 into the ΔfimAICDHF mutant reduced flhD and fliC transcript levels, the effects did not reach statistical significance" or "Compared to expression levels in the inoculum, mRNA levels of fimA were reduced in the phoN mutant recovered from the cecum but this difference did not reach statistical significance (P=0.07)". They should be changed into "Introduction of pTS42 into the ΔfimAICDHF mutant DID NOT CHANGE SIGNIFICANTLY the flhD and fliC transcript levels" and "mRNA levels of fimA in the phoN mutant recovered from the cecum DID NOT DIFFER SIGNIFICANTLY from those in the inoculum", respectively, because this is the actual meaning of statistical significance. Simply provide all p values so the reader can decide whether the effect observed may indeed be biologically interesting.
Referee #2
In this study, Sterzenbach et al. provide an interesting explanation for the observation that although Salmonella enterica have multiple fimbrial operons, production is limited to type I fimbriae encoded by fimAICDHF in laboratory grown cultures. The authors show the inhibition of the plasmid pefACDEF-encoded fimbrial expression occurs through the titration of the RNA binding protein CsrA by the 5' UTR of the fimAICDHF transcript (in conjunction with the CsrB and CsrC small RNAs). This novel mechanism of an mRNA acting as a titrator of CsrA to help coordinate the hierarchical control of fimbrial expression is well supported by the data presented in the paper.
My main comment is that parts of the manuscript need to be re-written to clarify the logic of the study. For example, in the abstract, the authors need to provide some information on how the "unlikely culprit" was found, and in the results section, the authors need to introduce/define genes such as sirA , csrA, csrB and csrC before describing the effects of the mutations.
More minor comments:
1. I think it would be useful to compare the regulatory role of the fimA 5' UTR with the regulatory effects of the chb mRNA in the Discussion. Tables 1 and 2 Figure 5A (i.e. fimA 5' UTR transcript levels in fimAICDHF mutant), which was below the limit of detection (i.e. < 1,000 copies per microgram of RNA). We also performed Northern blot analysis, which demonstrated that quantitative real-time PCR is more sensitive and easier to quantify. The reverse complement of the fimA 5'-UTR was in vitro transcribed to generate a DIGlabeled probe for Northern blotting. The RNA concentration of in vitro transcribed fimA 5'-UTR was determined and serial 10-fold dilutions were separated on a 1.5% agaroseformaldehyde gel, transferred onto a positively charged nylon membrane by passive capillary transfer and hybridized with the DIG-labeled probe. Northern blot enabled us to semi-quantitatively detect between 108 and 1010 copies of fimA 5'-UTR mRNA per lane. In contrast, quantitative real-time PCR enabled measurements of fimA 5'-UTR concentrations ranging between 104 and 109 molecules per reaction. Since real-time PCR represents a method that is not only more quantitative but also approximately 10,000-fold more sensitive, we respectfully disagree with this reviewer that Northern blot is a superior method that should be used to analyze mRNA.
Suggestions regarding figures: --

The next problem arising from the present copy number estimates is the actual numbers and potencies of CsrA binding sites. Even though CsrB appears to be 3 to 4 times less abundant than the 5' UTR of fimAICDHF, it still has 18 binding sites for CsrA versus 2 on the fimbrial messenger. This gives an about threefold higher absolute number of CsrA binders provided by CsrB/C, compared to the 5' UTR of fimAICDHF. The Kd for the 5' fimAICDH-CsrA complex estimated by EMSA (Fig. 4D) appears to be close to 150 nM, which is way above the 20 pM (!) Kd reported earlier for CsrB (Martinez et al., Mol Microbiol 2011). Given these simple calculations, it is very hard to understand that csrBC or sirA deletions have less an effect on pefACDEF expression than the deletion of fimAICDH (Figures 1A, 2C-D, and 3C). Considering those aforementioned parameters, the 5' UTR of fimAICDHF simply would not have enough clout to impose any kind of CsrA-mediated regulation on pefACDEF.
RESPONSE: The reviewer raises an interesting point. The EMSA of CsrA binding to the S. Typhimurium fimA 5'-UTR looks very similar to that of CsrA binding to the E. coli csrA 5'-UTR, which has been calculated to have a Kd of 27 nM . As the reviewer points out correctly, CsrB and CsrC have a much higher affinity for CsrA (i.e. a Kd of 20 pM has been reported for CsrB) (Martinez et al., 2011) . So why does deletion of fim have a larger effect on PefA expression than a deletion of csrB and csrC? The answer is likely related to the fact that deleting csrB and csrC has additional consequences on CsrA function. First, CsrA activates transcription of csrB/C and represses CsrB/C turnover through a negative feedback loop that is interrupted in a csrBC mutant, but not in a mutant lacking the fim 5'-UTR (Suzuki et al., 2006; Weilbacher et al., 2003) . Second, due to the high affinities of CsrB and CsrC for CsrA, deletion of csrB and csrC increases the availability of CsrA to bind its own 5'-UTR, which results in auto-repression of CsrA in a csrBC mutant . Since the fim 5'-UTR has a lower affinity for CsrA, deletion of the fim 5'-UTR would likely produce comparatively small effects on CsrA auto-regulation.
It would generally be helpful if the authors mapped the binding sites of CsrA in the 5'
UTRs of the fim and pet transcripts more precisely, e.g. using RNA footprinting methods or a more extensive mutational analysis. RESPONSE: We performed a more extensive mutational analysis to more precisely map the binding sites of CsrA in the 5'-UTRs of the fim and pef transcripts as suggested. The GGA motif is located at the beginning of the pef transcript (nucleotides 12-14 of the mRNA). When we mutated nucleotides directly adjacent to the GGA motif (T11A, A15T) or in a distance of one nucleotide (C10G, A16T) or two nucleotides (G9C, A17T) from the GGA motif, no electrophoretic shift with CsrA was observed in a RNA EMSA. However, mutation of nucleotides located in a distance of three bases from the GGA motif (T8A, T18A) did no longer prevent an electrophoretic shift with CsrA. The fim 5'UTR contains GGA motifs at nucleotides 102-105 and 157-159 of the mRNA. Mutations that changed both GGA motifs to CCA (G102C, G103C, G157C, G158C) abrogated the electrophoretic shift observed with CsrA. Mutating three adjacent nucleotides upstream and downstream of each GGA motif (A99T, C100G, A101T, T105A, G106C, C107G, A154T, C155G, A156T, T160A, G161C, C162G) resulted in a electrophoretic shift with CsrA. Similarly, a electrophoretic shift with CsrA was observed with a construct in which mutations were introduced that were at a distance of at least three nucleotides from each GGA motif (T96A, T97A, T98A, A108T, G109C, A110T, C151G, C152G, G153C, C163G, G164C, A165T). These experiments located the CsrA binding sites in the 5'-UTRs of the fim and pef transcripts to the central GGA motifs. These new data are now included in Figure panels 3G , 4F and 4G of the revised manuscript.
The conclusion that CsrA does not affect fimAICDH expression seems incorrect.
Moreover, it directly contradicts the results reported in the cited paper by Teplitski et al. 2006 (in Microbiology) . Figure 1C of the present manuscript suggests that in a sirA background, fimA is less expressed at the protein level than in WT. Figure 4D- Figure panel 3B of the revised manuscript. Importantly, these new data do not support the reviewer's suspicion that CsrA directly represses FimAICDHF translation. As pointed out by the reviewer, our results seem to contradict previous observations by Brian Ahmer's group (Teplitski et al., 2006) . However, it is my understanding from my correspondence with Dr. Ahmer that the effect of SirA on fim expression is very small when looking at chromosomal copies of sirA and it only reached significant levels when sirA was expressed from a plasmid, which would make this an observation with questionable in vivo relevance. All our studies were performed with chromosomal copies of regulators expressed at physiological levels.
The latter impression is further strengthened by the results of overexpression of the 5' UTR of fimAICDHF. First, let us consider the title of the section on p. 9 "The 5'-UTR of the fimAICDHF transcript is sufficient for suppressing PefA expression". The most straightforward experiment to support such a claim is to measure the PefA level in a strain where only the ORFs of the fimAICDHF operon are deleted while the 5' UTR is preserved and expressed under control of its native promoter. This has not been done. RESPONSE:
The fimAICDHF-mutant we used still carries the 5'-UTR of the fim-operon containing the GGA motif but expression levels were not detectable by real-time PCR, presumably because this fragment of the fim 5'-UTR is not very stable. So, the experiment the reviewer suggests has been done. However, due to the instability of the fim 5'-UTR transcript it was not feasible to address our question using this construct, which is why we decided to overexpress the 5'-UTR using a plasmid.
Instead, the authors decided to overexpress the 5' UTR which, by the way, may accumulate to transcript levels (RNA copy number) far above that of the native mRNA. Surprisingly, Fig. 5A shows that the "overexpression" yielded much less transcript from the 5' UTR of fimAICDHF than the native promoter.
RESPONSE: Given the instability of the chromosomal fim 5'-UTR (see above) we do not think it was surprising that overexpression of the unstable fim 5'-UTR fragment from a plasmid yielded less RNA than expression of the stable fimAICDHF transcript from it's native promoter in the chromosome.
Unexplainably, these levels were fully sufficient to repress pefA expression in Fig. 4C but failed to produce any noticeable effect on flhDC/fliC, as stated on page 12. RESPONSE: First of all, the fim 5'-UTR expressed from a plasmid was not "fully" sufficient" to repress pefA expression, but it only partially complemented the mutant. Secondly, the finding that expression of the fim 5'-UTR has different effects on different transcripts is not necessarily "unexplainable". As can be seen from the results of our RNA EMSAs, CsrA causes an electrophoretic shifts of the fim 5'-UTR at a concentration that is lower than that needed for the pef 5'-UTR, suggesting that the former has a higher affinity for CsrA. Thus, the fim 5'-UTR is predicted to be very effective in competing with the pef 5'-UTR for CsrA binding, thereby reducing pefA mRNA levels. In contrast, mRNA's that have a similar or higher affinity for CsrA than the fim 5'-UTR will be affected less by expressing the fim 5'-UTR. Fig. 5B-C) . RESPONSE: Please note that our measurements of "tiny" differences were not attempts to assess the biological relevance of our regulatory mechanism. Instead, we attempted to measure the effectiveness of complementing the chromosomal fimAICDHF mutation with the fim 5'-UTR expressed from the pTS42 plasmid. The plasmid produced 10-fold less fim 5'-UTR than the chromosomal copy of the operon in the Salmonella wild type and as a result the complementation was only partial (i.e. the differences were "tiny"). To assess the biological relevance of the regulatory mechanism, one has to compare flhD and fliC expression levels between the wild type and the fimAICDHF mutant, which were about 3-fold.
On the other hand, it produced a very convincing effect (~100-fold reduction) on pefA (Fig. 5D) suggesting that the latter would be the only regulated target by fimAICDHF through CsrA. This substantially weakens the authors' claim that CsrA mediates any effect of one fimbrial operon on the other. RESPONSE: I am not sure I understood what the reviewer was trying to say. Binding of the fim 5'UTR to CsrA "produced a very convincing effect (~100-fold reduction) on pefA" but this "substantially weakens the authors' claim that CsrA mediates any effect of one fimbrial operon on the other"? I do think our data show convincingly that binding of the fim 5'UTR to CsrA represses pef expression, thereby explaining how expression of one fimrbial operon can affect expression of another. This view is shared by reviewer 2, who states that "this novel mechanism of an mRNA acting as a titrator of CsrA to help coordinate the hierarchical control of fimbrial expression is well supported by the data presented in the paper". Perhaps the reviewer meant to say that the effect of the fim 5'UTR on pef expression was larger than that on other CsrA-regulated targets. This point is well taken. The regulatory mechanism proposed here is predicted to have the largest effects on mRNA's that have a lower affinity to CsrA than the fim 5'UTR. One such mRNA is the pef transcript. We do not know how many other CsrA regulated transcripts (there are more than 800 in E. coli) will fall into this category. But there is also a second category of CsrA-regulated mRNAs, namely those that that have a similar or higher affinity for CsrA than the fim 5'UTR, and the regulatory mechanism proposed here is predicted to produce smaller regulatory effects on these targets. In summary, expression of some targets (such as pef) will be affected markedly, while the effect on the expression of other CsrA-regulated targets (such as flhD) will be smaller. (Yakhnin et al., Mol Microbiol 2013) . Importantly, the comparison which should normally be considered on Figure 6B is We agree that competition of CsrA with RNase E is mere inference and have removed this speculation from the discussion. The reviewer points out correctly that the regulatory mechanism described here is not the only one controlling expression of Pef fimbriae in vivo. That is, other mechanisms are responsible for increased pefA expression of the pefACCA mutant cultured in vitro compared to its recovery from the cecum. This is not surprising, since expression of most Salmonella genes is controlled by a multitude of regulators. However, the relevant question is not whether there are regulatory mechanisms in addition to the one proposed here that contribute to fimbrial expression. Of course there are additional mechanisms at work as well. The relevant question is whether the mechanism proposed here is relevant in an animal. To answer this question, one has to compare in vivo gene expression (i.e. pefA expression in the cecum) in a strain in which the regulatory mechanism is active (i.e. the wild type) with that in a strain in which the regulatory mechanism is inactive (i.e. the pefACCA mutant). This comparison shows a 10-fold difference in pefA expression, suggesting that the regulatory mechanism proposed here is operational in vivo and changes Salmonella gene expression in the murine cecum. Thank you for submitting your revised manuscript to the EMBO Journal. Your study has now been re-reviewed by referee #1. As you can see below the referee appreciates the introduced changes and supports publication here. There are just a few remaining comments that I would like you to respond to in a final revision.
REFEREE REPORT Referee #1
The argumentation provided by the authors in their rebuttal is plausible and, together with the additional experimental evidence, gives solid support to the proposed mechanism. This study can be recommended for publication once the following minor comments have been addressed in the text:
1. The differential affinities reflected in the hierarchy of observed effects of the different CsrAbinding RNAs are of crucial importance for the mechanics of the system presented in the paper. Following the authors' explanations in point #5, it should be clearly stated in the discussion part that the regulation described is only possible because the pef mRNA is a low-affinity CsrA target so it can be readily affected by the high-affinity fimA 5'-UTR. At the same time, the fimA 5'-UTR, still being quite a weak binder of CsrA, is unlikely to off-target most of the known high-affinity CsrAbinding targets like hilD or flhD, providing a certain hierarchy of regulation within the CsrA regulon as a whole.
2. CsrA autoregulation is a well-taken point. Please include this important aspect in Fig. 7 .
3. The mutation analysis of the pef 5'-UTR should be interpreted more carefully. There is an apparent discrepancy, for instance, when the T11A, A15T mutant is considered. The mutated site (GCAGGATA) matches the consensus for CsrA binding (ACAAGGATG) even better than the original one (GCTGGAAA), yet there is no interaction. This contradiction is readily solved if one considers the structural context of all studied mutations. Secondary structure predictions suggest a
